Neocolipor

Neocolipor is given to female pigs – both sows and gilts - in order to immunise their offspring against neonatal enterotoxicosis. The vaccine is given by injection into a muscle and is intended for use 5-7 weeks before the birth of the litter (farrowing), with a second vaccination at 2 weeks prior to farrowing. A booster vaccination is given 2 weeks prior to each subsequent farrowing.

The medicine can only be obtained with a prescription.

For more information about using Neocolipor, see the package leaflet or contact your veterinarian or pharmacist.

Neocolipor is a vaccine. Vaccines work by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against a disease. Vaccination of sows and gilts enables the offspring to receive a passive immunity during their first days of life against neonatal enterotoxicosis caused by E. coli strains carrying the adhesins F4, F5, F6 and F41.

A number of trials were carried out in both the laboratory and in the field in order to assess the efficacy of the product. Safety data were also presented for the recommended use of the product both under laboratory conditions and in the field. Safety of the product was satisfactorily demonstrated.

The results presented showed statistical significance between vaccinates and non-vaccinates and thus demonstrated the efficacy of the vaccine. Re-vaccination was shown to be effective at the intervals recommended.

Vaccination may cause a slight rise in the animal’s body temperature (less than 1.5°C during a maximum period of 24 hours).

For the full list of side effects and restrictions of Neocolipor, see the package leaflet.

Safety information has been included in the summary of product characteristics and the package leaflet for Neocolipor, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.

In the case of accidental self injection, seek medical advice immediately and show the package insert or label to a physician.

The withdrawal period is the time required after administration of a medicine before an animal can be slaughtered and the meat used for human consumption.

The withdrawal period for Neocolipor is zero days (the vaccine does not contain any ingredients that are likely to pose a risk for consumers of vaccinated animals at the recommended dose).

The European Medicines Agency decided that Neocolipor’s benefits are greater than its risks and it can be authorised for use in the EU.

Neocolipor received a marketing authorisation valid throughout the EU on 9 August 2002.